Healthcare company DexCom, Inc. (NASDAQ: DXCM) announced preliminary results for the fourth quarter of 2023, reporting an estimated double-digit increase in revenues.
- Fourth-quarter revenue, unaudited, is expected to be at least $1.03 billion, which represents an increase of 26% over the same period of 2022
- US revenue is expected to be around $765 million in the December quarter, which is up 26% over the fourth quarter of the prior year
- At $265 million, international revenue is estimated to be higher by 27% from the prior-year quarter
- Stelo, the company’s new glucose sensor for people with type-2 diabetes who do not use insulin, has been submitted to the FDA for review
- For FY24, the company expects revenues of $4.15-4.35 billion, representing expected organic growth of 16-21% Year-over-year
- Full-year adjusted gross profit margin is expected to be approximately 63 – 64%
- The management is looking for an adjusted operating margin of around 20% for fiscal 2024
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Infographic: How Lennar Corporation (LEN) performed in Q3 2024
Lennar Corporation (NYSE: LEN) reported total revenues of $9.4 billion for the third quarter of 2024, which was up 8% from the same period last year. Net earnings attributable to
FDX Earnings: FedEx Q1 2025 revenue and profit miss analysts’ estimates
Cargo giant FedEx Corporation (NYSE: FDX) Thursday reported a decrease in revenues and adjusted earnings for the first quarter of 2025. The results also fell short of expectations. First-quarter earnings,
Signet (SIG) remains optimistic about its fiscal year 2025 performance, here’s why
Shares of Signet Jewelers Limited (NYSE: SIG) were up over 4% on Thursday. The stock has gained 24% over the past one month. The jewelry retailer saw revenue and profits
